Saxenda Is Being Discontinued in January 2027: What Is Actually Ending, and What Switching Really Costs You

Is Saxenda being discontinued?

One product in the liraglutide family is ending. Four others are not, and the difference between them comes down to a single database field that most coverage of this news collapses. Yes, Saxenda is being discontinued. Novo Nordisk says on its own patient site that it is giving advance notice of the decision, with last shipments to wholesalers taking place in late January 2027, and that the decision is not the result of any safety or quality related concern (Saxenda, 2026). The same notice appears on Novo's clinician-facing page (NovoMedLink, 2026).

What is ending is the branded weight-management liraglutide and nothing else. Victoza, the branded type 2 diabetes liraglutide, is still marketed. So is the authorized generic that Teva distributes, and so are the generics from Hikma and Meitheal. If you take liraglutide for blood sugar rather than for weight, this announcement does not describe your prescription.

One date is worth separating out before anything else. The FDA shortage record carries 08/25/2026, and that is the date the notice was posted, not the date supply stops. Treating it as a cutoff would push a patient into an unnecessary switch four or five months early. The only operative date anyone has published is late January 2027, and it comes from Novo rather than from the FDA.

What does the FDA shortage feed actually say about liraglutide right now?

We pulled the openFDA drug shortage endpoint on August 27, 2026 and it returned 11 liraglutide records against a database timestamp of the same day. Nine read Current. Two read To Be Discontinued, and those two are separate events involving two different companies and two different FDA applications. Here is every record, exactly as the feed carries it.

The reason this table matters more than the headline is that the feed's own naming makes the story easy to get backwards. All 11 records share the same generic name, liraglutide, and the Saxenda and Victoza records share the same company name, Novo Nordisk, Inc. Read only those two fields and you would conclude that Novo is discontinuing liraglutide. The only fields that discriminate are the presentation string and the brand name, and both of them say SAXENDA on the discontinued record and nothing else. Isolating the brand confirms it: a query restricted to SAXENDA returns exactly two records, both dated 08/25/2026, and no other brand appears.

Is Victoza being discontinued too?

No. Victoza is a separate FDA application, NDA 022341, and both of its presentations read Current in the same pull. It is not on the discontinuation notice and Novo's notice does not mention it.

That said, Current is not the same as comfortable. Both Victoza presentations sit at Limited Availability with an estimated shortage duration listed as TBD, and the more recent of the two was revised on the same day the Saxenda notice went up. Anyone reading this page and thinking of asking a prescriber about branded liraglutide should know that the branded diabetes line is itself supply constrained with no published end date, while the unbranded lines are the ones currently reading Available.

There is also a second discontinuation sitting in the same feed that is easy to merge into this story by mistake. Teva's own generic liraglutide, application ANDA 214568 under NDC 0480-7250-46, has read To Be Discontinued since May 14, 2026. It is an earlier event, a different company's application, and unrelated to the Saxenda notice. Confusingly, Teva also distributes Novo's authorized generic under a different NDC prefix, and that line reads Available, so the same distributor name appears on both a discontinued record and a healthy one.

Is generic liraglutide a substitute for Saxenda?

Not on the labels as written, and this is the mistake most likely to do real harm. Every marketed liraglutide generic is a generic of Victoza, not of Saxenda. There is no generic Saxenda.

We read the generic labels directly rather than inferring this. The Meitheal label (openFDA, 2026) is indicated only as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, and it caps at 1.8 mg per day. The Hikma label and the Teva-distributed authorized generic label carry the same indication and the same ceiling. None of the three mentions a 3 mg dose or a weight-management use.

The application record says the same thing from the other direction. A pull of the Drugs@FDA application data returns 14 liraglutide products. Saxenda and Victoza are both flagged as reference drugs, and every abbreviated application in the set, from Teva, Hikma, Meitheal, Sandoz, Lupin, Biocon, Mylan, Fresenius Kabi and Orbicular, is 18 mg per 3 mL. That strength is worth pausing on, because it is the strength of both brands: Saxenda and Victoza are the same 6 mg per mL concentration in the same 3 mL pen, and they differ in the doses the pen is built to deliver. So the application record cannot tell you on its own which brand a generic was approved against. The labels can, and all of them read type 2 diabetes. Not one carries a weight-management indication.

Is there a dose conversion from Saxenda to Wegovy or Zepbound?

There is not one in any FDA label, and that absence is the single most useful thing this page can tell you. We ran a full-text search of the complete Saxenda, Wegovy and Zepbound label records from openFDA. The words switching, conversion and transition returned zero occurrences in all three. Zepbound uses the word switch six times: four advising patients on oral contraceptives to move to a non-oral method, and two describing a trial in which patients were randomized to stay on the drug or switch to placebo. None of the six is guidance on moving between GLP-1 medications. Wegovy's one mention of liraglutide sits inside the thyroid C-cell tumor boxed-warning discussion, not in any dosing context. There is no equivalence table, no milligram mapping, and no shortened titration route published between these drugs.

Read the three rows together and the practical consequence is visible without anyone having to invent a ratio. Both weekly schedules are written as initiation schedules with no carve-out for patients who have taken a GLP-1 before. On the labels as they stand, sitting at the top liraglutide dose confers no head start, and someone leaving Saxenda 3 mg daily starts a new escalation from the bottom. For Wegovy that is a 16 week climb to maintenance (Wegovy label, 2024). For Zepbound the first dose is explicitly a starter dose that is not approved to stay on (Zepbound label, 2026).

What happens if your Saxenda supply lapses before you switch?

You lose your titration, and the window is far shorter than most people expect. The Saxenda label instructs that if more than 3 days have elapsed since the last dose, treatment is reinitiated at 0.6 mg daily and the escalation schedule is followed again from the start, to reduce the risk of the gastrointestinal reactions associated with reinitiation (Saxenda prescribing information, 2026).

Three days. Not three weeks. That is the rule for restarting the same drug you were already on, and it is the reason a supply gap between now and January 2027 is worth planning around rather than absorbing. A pharmacy backorder over a long weekend is enough to trigger it.

One more line from the same label is worth carrying into any conversation about overlapping products during a transition, and it is broader than it first looks. Saxenda's own Limitations of Use state that coadministration with other liraglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. The generic liraglutide labels carry only the narrower half of that, covering other liraglutide products. Read the Saxenda wording as it stands and it reaches the exact move this page is about: running Saxenda alongside Wegovy or Zepbound during a changeover is not something its label endorses, and neither is running two liraglutide products at once.

Who still dispenses liraglutide or Saxenda in 2026?

Seven programs in our comparison carry some form of liraglutide, and what they dispense differs enough that the distinction matters more than the ranking. The table is sorted by our score, which is computed from our published methodology and never from a commercial relationship.

Three of the seven carry brand Saxenda, and those are the ones whose liraglutide offering is directly affected by the January 2027 date. Four dispense compounded liraglutide, which is a different regulatory question entirely: the FDA proposed on April 30, 2026 to exclude liraglutide along with semaglutide and tirzepatide from the 503B bulk drug substances list, comments closed July 30, 2026, and no final rule had been announced when we last checked. Our full breakdown of that proposal explains what it would and would not change, and the brand versus compounded comparison covers the difference in what you are actually buying.

If a program is offering you generic liraglutide as a weight-management option, the caveat from earlier applies without modification. It is a Victoza generic with a type 2 diabetes indication and a 1.8 mg ceiling, and it should be discussed as that rather than as a Saxenda replacement.

What should you take to a prescriber before January 2027?

This is a prescriber's decision and there is no version of it a website should make for you. What a website can do is make sure you arrive with the right questions, because the useful facts here are the ones nobody volunteers.

Five things worth raising, in the order they tend to matter:

• •Confirm which liraglutide product you are actually on. Saxenda, Victoza and unbranded liraglutide have separate approval records and only one of them is ending.
• •Ask what the plan is for the gap. Given the 3 day reinitiation rule, a lapse of a long weekend restarts the titration on the drug you are already taking.
• •Ask what the starting dose would be on any new medication, and expect the answer to be the label's initiation dose rather than a dose matched to where you are now.
• •Ask about coverage before choosing a destination, because the daily and weekly products sit in different tiers on most formularies and a switch that works clinically can still fail at the pharmacy counter.
• •If compounded liraglutide is offered, ask which pathway and which pharmacy, and get the answer in the record rather than from a marketing page.

If the conversation moves toward a weekly medication, our comparisons of Wegovy and Zepbound lay out what each one is approved to do, and the Wegovy versus Zepbound breakdown covers the trial evidence side by side. If you want to narrow the provider question first, the match quiz sorts programs by what you are actually optimizing for.

Frequently Asked Questions

The questions below come up most often around a discontinuation notice, and each answer is limited to what a cited record actually supports.

When exactly does Saxenda stop being available?

Novo Nordisk states that last shipments to wholesalers take place in late January 2027 (Saxenda, 2026), and the FDA record says the product will be available until discontinuation in January 2027. Neither source publishes a date on which pharmacy stock runs out, which will depend on what individual wholesalers and pharmacies are holding.

Is Saxenda being discontinued because it is unsafe?

Novo's notice states that the decision is not the result of any safety or quality related concern. The FDA record lists the reason as discontinuation of the manufacture of the drug. Neither source gives a further explanation, and no safety action appears alongside the notice.

Can I switch to generic liraglutide and keep my dose?

No generic matches the Saxenda dose. Every marketed liraglutide generic is approved against Victoza, is indicated for type 2 diabetes, and caps at 1.8 mg daily, so a patient maintained at 3 mg daily cannot be matched on dose. Whether a lower dose is still worth using is a clinical decision, not a substitution.

How much Wegovy or Zepbound equals 3 mg of Saxenda?

No published label answers this. A full-text search of the Saxenda, Wegovy and Zepbound labels returns no switching, conversion or transition guidance, and both weekly products are written with a single initiation schedule that makes no allowance for prior GLP-1 exposure. Any equivalence chart you find was constructed by whoever published it.

Does this notice affect Victoza patients or diabetes prescriptions?

No. Victoza sits under a separate application and reads Current in the FDA feed, as do the Hikma, Meitheal and Teva-distributed generics. The one caveat is that both Victoza presentations carry a Limited Availability flag with the shortage duration listed as TBD, which is a supply constraint rather than a discontinuation.

Sources